Markus G. Seidel1,2,9, Luka Brcic3, Gerald Hoefler3, Caroline Hutter4, 5, Milen Minkov4, 6, Laura Sophie Steffen1, Armin Zebisch7, 8, 9, Martin Benesch1
1Division of Pediatric Hematology-Oncology, Department of Pediatrics and Adolescent Medicine, Medical University of Graz, Graz, Austria
2Research Unit for Pediatric Hematology and Immunology, Medical University of Graz, Graz, Austria
3Diagnostic and Research Institute of Pathology, Medical University of Graz, Graz, Austria
4International LCH Study Reference Center, CCRI, St. Anna Kinderkrebsforschung, Medical University of Vienna, Austria
5St. Anna Children’s Hospital, Medical University of Vienna, Austria
6Medical Faculty, Sigmund Freud Private University, Vienna, Austria
7Division of Hematology, Medical University of Graz, Graz, Austria
8Otto-Loewi-Research Center for Vascular Biology, Immunology and Inflammation, Division of Pharmacology, Medical University of Graz, Graz, Austria
9Correspondence: Markus G Seidel , MD, Division of Pediatric Hematology-Oncology, Department of Pediatrics and Adolescent Medicine, Auenbruggerplatz 38, Medical University of Graz, A-8036 Graz, Austria; e-mail: markus.seidel@medunigraz.at ;Armin Zebisch , MD, Division of Hematology, Medical University of Graz, Graz, Austria Auenbruggerplatz 38, A-8036 Graz, Austria; e-mail: armin.zebisch@medunigraz.at .
Word count: 536
Key words: BRAF; KRAS; juvenile xanthogranuloma (JXG); vemurafenib; MAPK/ERK signaling pathway; Langerhans cell histiocytosis (LCH).